Copyright Reports & Markets. All rights reserved.

Global Rotavirus Infections Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Rotavirus Infections Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Rotavirus Infections Drug Market Size Growth Rate by Product
      • 1.4.2 RV-3BB
      • 1.4.3 RV-625
      • 1.4.4 UMN-2001
      • 1.4.5 Rotavac-5C
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Rotavirus Infections Drug Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Rotavirus Infections Drug Market Size
      • 2.1.1 Global Rotavirus Infections Drug Revenue 2014-2025
      • 2.1.2 Global Rotavirus Infections Drug Sales 2014-2025
    • 2.2 Rotavirus Infections Drug Growth Rate by Regions
      • 2.2.1 Global Rotavirus Infections Drug Sales by Regions
      • 2.2.2 Global Rotavirus Infections Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Rotavirus Infections Drug Sales by Manufacturers
      • 3.1.1 Rotavirus Infections Drug Sales by Manufacturers
      • 3.1.2 Rotavirus Infections Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Rotavirus Infections Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Rotavirus Infections Drug Revenue by Manufacturers
      • 3.2.1 Rotavirus Infections Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Rotavirus Infections Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Rotavirus Infections Drug Price by Manufacturers
    • 3.4 Rotavirus Infections Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Rotavirus Infections Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Rotavirus Infections Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Rotavirus Infections Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Rotavirus Infections Drug Sales by Product
    • 4.2 Global Rotavirus Infections Drug Revenue by Product
    • 4.3 Rotavirus Infections Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Rotavirus Infections Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Rotavirus Infections Drug by Countries
      • 6.1.1 North America Rotavirus Infections Drug Sales by Countries
      • 6.1.2 North America Rotavirus Infections Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Rotavirus Infections Drug by Product
    • 6.3 North America Rotavirus Infections Drug by End User

    7 Europe

    • 7.1 Europe Rotavirus Infections Drug by Countries
      • 7.1.1 Europe Rotavirus Infections Drug Sales by Countries
      • 7.1.2 Europe Rotavirus Infections Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Rotavirus Infections Drug by Product
    • 7.3 Europe Rotavirus Infections Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Rotavirus Infections Drug by Countries
      • 8.1.1 Asia Pacific Rotavirus Infections Drug Sales by Countries
      • 8.1.2 Asia Pacific Rotavirus Infections Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Rotavirus Infections Drug by Product
    • 8.3 Asia Pacific Rotavirus Infections Drug by End User

    9 Central & South America

    • 9.1 Central & South America Rotavirus Infections Drug by Countries
      • 9.1.1 Central & South America Rotavirus Infections Drug Sales by Countries
      • 9.1.2 Central & South America Rotavirus Infections Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Rotavirus Infections Drug by Product
    • 9.3 Central & South America Rotavirus Infections Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Rotavirus Infections Drug by Countries
      • 10.1.1 Middle East and Africa Rotavirus Infections Drug Sales by Countries
      • 10.1.2 Middle East and Africa Rotavirus Infections Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Rotavirus Infections Drug by Product
    • 10.3 Middle East and Africa Rotavirus Infections Drug by End User

    11 Company Profiles

    • 11.1 Beijing Minhai Biotechnology Co Ltd
      • 11.1.1 Beijing Minhai Biotechnology Co Ltd Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Products Offered
      • 11.1.5 Beijing Minhai Biotechnology Co Ltd Recent Development
    • 11.2 Bharat Biotech International Ltd
      • 11.2.1 Bharat Biotech International Ltd Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bharat Biotech International Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bharat Biotech International Ltd Rotavirus Infections Drug Products Offered
      • 11.2.5 Bharat Biotech International Ltd Recent Development
    • 11.3 Biological E Ltd
      • 11.3.1 Biological E Ltd Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Biological E Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Biological E Ltd Rotavirus Infections Drug Products Offered
      • 11.3.5 Biological E Ltd Recent Development
    • 11.4 Curevac AG
      • 11.4.1 Curevac AG Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Curevac AG Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Curevac AG Rotavirus Infections Drug Products Offered
      • 11.4.5 Curevac AG Recent Development
    • 11.5 Medicago Inc
      • 11.5.1 Medicago Inc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Medicago Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Medicago Inc Rotavirus Infections Drug Products Offered
      • 11.5.5 Medicago Inc Recent Development
    • 11.6 Nanotherapeutics Inc
      • 11.6.1 Nanotherapeutics Inc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Nanotherapeutics Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Nanotherapeutics Inc Rotavirus Infections Drug Products Offered
      • 11.6.5 Nanotherapeutics Inc Recent Development
    • 11.7 Serum Institute of India Ltd
      • 11.7.1 Serum Institute of India Ltd Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Serum Institute of India Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Serum Institute of India Ltd Rotavirus Infections Drug Products Offered
      • 11.7.5 Serum Institute of India Ltd Recent Development
    • 11.8 UMN Pharma Inc
      • 11.8.1 UMN Pharma Inc Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 UMN Pharma Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 UMN Pharma Inc Rotavirus Infections Drug Products Offered
      • 11.8.5 UMN Pharma Inc Recent Development
    • 11.9 Wuhan Institute of Biological Products Co Ltd
      • 11.9.1 Wuhan Institute of Biological Products Co Ltd Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Products Offered
      • 11.9.5 Wuhan Institute of Biological Products Co Ltd Recent Development

    12 Future Forecast

    • 12.1 Rotavirus Infections Drug Market Forecast by Regions
      • 12.1.1 Global Rotavirus Infections Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Rotavirus Infections Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Rotavirus Infections Drug Market Forecast by Product
      • 12.2.1 Global Rotavirus Infections Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Rotavirus Infections Drug Revenue Forecast by Product 2019-2025
    • 12.3 Rotavirus Infections Drug Market Forecast by End User
    • 12.4 North America Rotavirus Infections Drug Forecast
    • 12.5 Europe Rotavirus Infections Drug Forecast
    • 12.6 Asia Pacific Rotavirus Infections Drug Forecast
    • 12.7 Central & South America Rotavirus Infections Drug Forecast
    • 12.8 Middle East and Africa Rotavirus Infections Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Rotavirus Infections Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Rotavirus Infections Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Rotavirus Infections Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Rotavirus Infections Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Rotavirus Infections Drug in these regions.
      This research report categorizes the global Rotavirus Infections Drug market by top players/brands, region, type and end user. This report also studies the global Rotavirus Infections Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Beijing Minhai Biotechnology Co Ltd
      Bharat Biotech International Ltd
      Biological E Ltd
      Curevac AG
      Medicago Inc
      Nanotherapeutics Inc
      Serum Institute of India Ltd
      UMN Pharma Inc
      Wuhan Institute of Biological Products Co Ltd

      Market size by Product
      RV-3BB
      RV-625
      UMN-2001
      Rotavac-5C
      Others
      Market size by End User
      Clinic
      Hospital
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Rotavirus Infections Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Rotavirus Infections Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Rotavirus Infections Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Rotavirus Infections Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Rotavirus Infections Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Rotavirus Infections Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now